International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
SARS-CoV-2 infection disrupts the immune control status in a male HIV-1 elite controller.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Chun-Yu, Wang Fu-Sheng, Jiao Yan-Mei
Аннотация
OBJECTIVE: To report a case of an HIV elite controller (EC) who developed disease progression following SARS-CoV-2 infection, characterized by the breakdown of prior immune control.
CASE PRESENTATION: We report a case of a Chinese male EC with HIV-1 CRF01_AE and protective HLA-B*57:01, who had sustained undetectable viral load and stable CD4+ T-cell counts for over 10 years. Following SARS-CoV-2 infection, he developed persistent HIV viral rebound (peaking at 4430 copies/ml) for eight months, accompanied by a profound CD4+ T-cell decline to 174 cells/µl, and subsequently initiated antiretroviral therapy. After treatment, viral load was effectively suppressed, and immune function gradually recovered.
CONCLUSION: This is the first reported case of an HIV EC losing immune control after SARS-CoV-2 infection, leading to prolonged viral rebound and severe CD4+ decline. Our observation demonstrates that elite control is conditional and can be disrupted by major immunological challenges, supporting enhanced surveillance of ECs during intercurrent infections.
CASE PRESENTATION: We report a case of a Chinese male EC with HIV-1 CRF01_AE and protective HLA-B*57:01, who had sustained undetectable viral load and stable CD4+ T-cell counts for over 10 years. Following SARS-CoV-2 infection, he developed persistent HIV viral rebound (peaking at 4430 copies/ml) for eight months, accompanied by a profound CD4+ T-cell decline to 174 cells/µl, and subsequently initiated antiretroviral therapy. After treatment, viral load was effectively suppressed, and immune function gradually recovered.
CONCLUSION: This is the first reported case of an HIV EC losing immune control after SARS-CoV-2 infection, leading to prolonged viral rebound and severe CD4+ decline. Our observation demonstrates that elite control is conditional and can be disrupted by major immunological challenges, supporting enhanced surveillance of ECs during intercurrent infections.